Type
Internal restructuring
Country
Germany
Region
Baden-Württemberg; Tübingen;
Location of affected unit(s)
Ulm, Blaubeuren
Sector
(10 - 33) Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

150 - 200 jobs
Number of planned job losses
Job loss
Announcement Date
6 August 2025
Employment effect (start)
1 April 2025
Foreseen end date
31 December 2026

Description

Teva, an Israeli pharmaceutical company, plans to cut around 150 jobs at its headquarters in Ulm and its production site in Blaubeuren-Weiler (Baden-Württemberg). 50 jobs were already cut in the spring, and a further 150 jobs are to be cut by the end of 2026.

The reason for the measure is cost-cutting targets set by the parent company in Israel and efficiency gains through automation and the use of artificial intelligence.

The jobs are to be cut mainly through termination agreements with severance payments and not filling vacant positions; redundancies are not currently planned.

The Mining, Chemical and Energy Industrial Union (IGBCE) has expressed concerns about the additional pressure on remaining employees, and the social partners have held talks on voluntary redundancy arrangements.

Teva Germany employs around 2,900 people and has sites in Ulm and Blaubeuren-Weiler.


Sources

Citation

Eurofound (2025), Teva, Internal restructuring in Germany, factsheet number 203184, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203184.